Scopus h-index:58
- Home
- Profiles
Video Visit Available
Accepting New Patients
Mount Sinai Doctors
Video Visit Available
Accepting New PatientsMatthew Galsky, MD
Cancer (Oncology)
No Patient Experience Ratings
Ruttenberg Treatment Center
212-241-6756
- About Me
- Clinical Focus
- Video
- Education & Certifications
- Awards
- Locations
- Insurance
- Publications
- Industry Relationships
About Me
Dr. Galsky is Professor of Medicine (Hematology and Medical Oncology), Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute, and Associate Director for Translational Research at The Tisch Cancer Institute. Dr. Galsky specializes in the care of patients with genitourinary malignancies—bladder, prostate, kidney, and testicular cancers. His research centers on team science-based approaches to dissecting the mechanistic underpinnings of response and resistance to novel bladder cancer therapies with a particular focus on immunotherapeutic approaches.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
About Me
Dr. Galsky is Professor of Medicine (Hematology and Medical Oncology), Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute, and Associate Director for Translational Research at The Tisch Cancer Institute. Dr. Galsky specializes in the care of patients with genitourinary malignancies—bladder, prostate, kidney, and testicular cancers. His research centers on team science-based approaches to dissecting the mechanistic underpinnings of response and resistance to novel bladder cancer therapies with a particular focus on immunotherapeutic approaches.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
About Me
Dr. Galsky is Professor of Medicine (Hematology and Medical Oncology), Director of Genitourinary Medical Oncology, Co-Director of the Center of Excellence for Bladder Cancer at The Tisch Cancer Institute, and Associate Director for Translational Research at The Tisch Cancer Institute. Dr. Galsky specializes in the care of patients with genitourinary malignancies—bladder, prostate, kidney, and testicular cancers. His research centers on team science-based approaches to dissecting the mechanistic underpinnings of response and resistance to novel bladder cancer therapies with a particular focus on immunotherapeutic approaches.
Language
Position
Hospital Affiliations
- The Mount Sinai Hospital
Clinical Focus
- Bladder Cancer
- Kidney Cancer
- Primary Pulmonary Hypertension
- Prostate Cancer
- Testicular Cancer
- Testicular Tumors
- Urologic Cancers
- Bladder Cancer
- Kidney Cancer
- Primary Pulmonary Hypertension
- Prostate Cancer
- Testicular Cancer
- Testicular Tumors
- Urologic Cancers
Video
Education
MD, Tufts University
Residency, Internal Medicine
Beth Israel Deaconess Medical Center GME
Fellowship, Medical Oncology
Memorial Sloan-Kettering Cancer Center
Awards
2003
American Society of Clinical Oncology Merit Award
1998
Medical Calss of 1928 Award (Tufts School of Medicine, Excellence in Anatomy)
1998
Leon Levinson Prize (Tufts School of Medicine, Excellence in Physiology)
1997
Alpha Omega Alpha Honor Society
Locations
Insurance Information
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
- Ruttenberg Treatment Center1470 Madison Avenue, 3rd Floor, New York, NY, 10029
- 1199 SEIU
- AETNA - Commercial
- AETNA - Medicare
- Affinity Medicaid-Medicare-Essential Exchange
- AgeWell New York
- Amidacare Medicaid
- CIGNA Healthcare
- Centivo
- Elderplan
- EmblemHealth - GHI-PPO
- EmblemHealth - HIP
- EmblemHealth - HIP-Medicaid
- EmblemHealth - HIP-Medicare
- Empire Blue Cross Blue Shield - Commercial/Exchange
- Empire Blue Cross Blue Shield - Healthplus FKA Amerigroup Medicaid
- Empire Blue Cross Blue Shield - Medicare
- Fidelis Health Care
- HealthFirst Medicaid
- HealthFirst Medicare
- Horizon NJ
- Hotel Trades
- Magnacare-Health Care
- Medicare
- Metroplus
- Multiplan PHCS
- NY Medicaid
- Oxford - Freedom & Liberty
- Partners Health Plan
- Select Health Medicaid - VNSNY
- Senior Whole Health
- United Health Care - Commercial
- United Health Care - Community Care Medicaid
- United Health Care - Empire Plan
- United Health Care - Oxford Care
- United Health Care - Top Tier
- VNSNY Choice Medicare
- VillageCareMax
- WellCare Health Plan
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Publications
Article:232
Review Article:86
Comment/Debate:15
Letter:18
Editorial:12
Chapter:8
Selected Publications
- Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score
- Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer
- Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary
- Real-world treatment patterns and clinical outcomes with first-line therapy in patients with locally advanced/metastatic urothelial carcinoma by cisplatin-eligibility
- Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors
- Clinical factors associated with outcome in solid tumor patients treated with immune-checkpoint inhibitors: a single institution retrospective analysis
- Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer
- Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials
- Androgen annihilation versus advanced androgen blockage as first line treatment for metastatic castration resistant prostate cancer: A systematic review and meta-analysis
- Tumor-Infiltrating Myeloid Cells Confer De Novo Resistance to PD-L1 Blockade through EMT–Stromal and Tgfb-Dependent Mechanisms
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Galsky during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Bristol-Myers Squibb
- Pfizer Inc.
- NuMab
- Incyte Corporation
- Rappta Therapeutics
- Curis Inc.
- FUJIFILM Medical Systems U.S.A., Inc.
- Genentech, Inc.
- Janssen Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Alligator
- Basilea
- Silverback
- AstraZeneca
- Seattle Genetics
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
- Rappta Therapeutics
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.